Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs.
SARS-CoV-2
breakthrough infections
vaccination
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
07 Feb 2022
07 Feb 2022
Historique:
received:
20
01
2022
revised:
29
01
2022
accepted:
31
01
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
27
2
2022
Statut:
epublish
Résumé
Despite an array of preventive global public health interventions, SARS-CoV-2 has continued to spread significantly, infecting millions of people across the globe weekly. Newer variants of interest and concern have continued to emerge, placing the need for policymakers to rethink prevention strategies to end the pandemic. The approval of SARS-CoV-2 vaccines for public health use in December 2020 was seen as a significant development towards pandemic control and possibly ending the pandemic. However, breakthrough infections have continued to be observed among the 'fully vaccinated', and the duration and sustainability of vaccine-induced immunity has remained a topical public health discourse. In the absence of accurate public health communication, the breakthrough infections and waning immunity concepts have potential to further compound vaccine hesitancy. With this viewpoint, we discuss breakthrough SARS-CoV-2 infections, waning immunity, the need for COVID-19 booster shots, vaccine inequities, and the need to address vaccine hesitancy adequately to propel global vaccination programs forward.
Identifiants
pubmed: 35214710
pii: vaccines10020252
doi: 10.3390/vaccines10020252
pmc: PMC8879800
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Front Physiol. 2017 Apr 25;8:233
pubmed: 28487657
JAMA Netw Open. 2021 Sep 1;4(9):e2126635
pubmed: 34591105
Lancet Respir Med. 2021 Dec;9(12):1354-1356
pubmed: 34599904
JAMA. 2021 Dec 14;326(22):2247-2249
pubmed: 34817538
J Med Econ. 2021 Jan-Dec;24(1):1248-1260
pubmed: 34844493
JAMA. 2021 Dec 28;326(24):2524-2526
pubmed: 34724529
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 33974565
Science. 2021 Dec 24;374(6575):1561-1562
pubmed: 34941414
Mayo Clin Proc. 2021 Mar;96(3):699-707
pubmed: 33673921
BMJ. 2021 Dec 3;375:n3011
pubmed: 34862175
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Clin Infect Dis. 2019 May 2;68(10):1623-1630
pubmed: 30204855
PLoS One. 2021 Oct 15;16(10):e0258820
pubmed: 34653228
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet Glob Health. 2021 Dec;9(12):e1624-e1625
pubmed: 34695370
Vaccines (Basel). 2021 Aug 13;9(8):
pubmed: 34452026
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Lancet Respir Med. 2021 Dec;9(12):1356-1358
pubmed: 34688435
Lancet Infect Dis. 2022 Jan;22(1):20
pubmed: 34953546
Croat Med J. 2021 Dec 31;62(6):630-633
pubmed: 34981696
Nature. 2021 Apr 29;:
pubmed: 33927403
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Risk Manag Healthc Policy. 2021 Aug 26;14:3575-3587
pubmed: 34475789
BMJ. 2021 Nov 17;375:e068302
pubmed: 34789505
Nature. 2021 Jan;589(7840):16-18
pubmed: 33340018
JAMA Intern Med. 2022 Feb 1;182(2):153-162
pubmed: 34962505
Vaccines (Basel). 2021 Feb 16;9(2):
pubmed: 33669441
Public Health Pract (Oxf). 2022 Jun;3:100223
pubmed: 34927108
BMJ. 2021 Dec 20;375:n3105
pubmed: 34930779
Hum Vaccin Immunother. 2020 Nov 1;16(11):2586-2593
pubmed: 32693678
BMJ. 2021 Sep 23;374:n2320
pubmed: 34556464
Emerg Microbes Infect. 2022 Dec;11(1):337-343
pubmed: 34935594
BMJ. 2021 Dec 14;375:n3079
pubmed: 34906956
Philos Trans R Soc Lond B Biol Sci. 2021 Jul 19;376(1829):20200274
pubmed: 34053264
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281